Annual EBITDA
-$25.52 M
+$32.01 M+55.64%
December 31, 2023
Summary
- As of February 7, 2025, LSTA annual EBITDA is -$25.52 million, with the most recent change of +$32.01 million (+55.64%) on December 31, 2023.
- During the last 3 years, LSTA annual EBITDA has fallen by -$6.44 million (-33.73%).
- LSTA annual EBITDA is now -11436.62% below its all-time high of -$221.20 thousand, reached on March 1, 1998.
Performance
LSTA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$5.29 M
+$184.00 K+3.36%
September 30, 2024
Summary
- As of February 7, 2025, LSTA quarterly EBITDA is -$5.29 million, with the most recent change of +$184.00 thousand (+3.36%) on September 30, 2024.
- Over the past year, LSTA quarterly EBITDA has increased by +$684.00 thousand (+11.44%).
- LSTA quarterly EBITDA is now -4186.64% below its all-time high of -$123.50 thousand, reached on March 1, 2003.
Performance
LSTA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$23.30 M
+$623.00 K+2.60%
September 30, 2024
Summary
- As of February 7, 2025, LSTA TTM EBITDA is -$23.30 million, with the most recent change of +$623.00 thousand (+2.60%) on September 30, 2024.
- Over the past year, LSTA TTM EBITDA has increased by +$2.21 million (+8.68%).
- LSTA TTM EBITDA is now -9980.02% below its all-time high of -$231.20 thousand, reached on March 1, 2000.
Performance
LSTA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
LSTA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +55.6% | +11.4% | +8.7% |
| 3 y3 years | -33.7% | +11.4% | +8.7% |
| 5 y5 years | -60.1% | +11.4% | +8.7% |
LSTA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +55.6% | at high | +86.0% | at high | +59.7% |
| 5 y | 5-year | -33.7% | +55.6% | -31.0% | +86.0% | -26.4% | +59.7% |
| alltime | all time | <-9999.0% | +72.7% | -4186.6% | +88.4% | -9980.0% | +75.1% |
Lisata Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$5.29 M(-3.4%) | -$23.30 M(-2.6%) |
| Jun 2024 | - | -$5.48 M(-16.4%) | -$23.93 M(-5.3%) |
| Mar 2024 | - | -$6.55 M(+9.7%) | -$25.28 M(-0.9%) |
| Dec 2023 | -$25.52 M(-55.6%) | -$5.98 M(+1.0%) | -$25.52 M(-2.0%) |
| Sep 2023 | - | -$5.92 M(-13.3%) | -$26.03 M(-55.0%) |
| Jun 2023 | - | -$6.83 M(+0.5%) | -$57.83 M(+0.2%) |
| Mar 2023 | - | -$6.80 M(+4.7%) | -$57.71 M(+0.3%) |
| Dec 2022 | -$57.53 M(+98.4%) | -$6.49 M(-82.8%) | -$57.53 M(-0.6%) |
| Sep 2022 | - | -$37.71 M(+461.8%) | -$57.88 M(+113.4%) |
| Jun 2022 | - | -$6.71 M(+1.5%) | -$27.12 M(-1.5%) |
| Mar 2022 | - | -$6.61 M(-3.3%) | -$27.54 M(-5.0%) |
| Dec 2021 | -$29.00 M(+51.9%) | - | - |
| Dec 2021 | - | -$6.84 M(-1.6%) | -$29.00 M(+5.1%) |
| Sep 2021 | - | -$6.95 M(-2.5%) | -$27.58 M(+6.2%) |
| Jun 2021 | - | -$7.13 M(-11.6%) | -$25.96 M(+12.3%) |
| Mar 2021 | - | -$8.07 M(+48.6%) | -$23.11 M(+21.1%) |
| Dec 2020 | -$19.08 M(-4.7%) | -$5.43 M(+1.8%) | -$19.08 M(+1.9%) |
| Sep 2020 | - | -$5.33 M(+24.7%) | -$18.72 M(+1.5%) |
| Jun 2020 | - | -$4.28 M(+5.8%) | -$18.44 M(-5.4%) |
| Mar 2020 | - | -$4.04 M(-20.2%) | -$19.49 M(-2.7%) |
| Dec 2019 | -$20.03 M(+25.7%) | -$5.07 M(+0.2%) | -$20.03 M(+8.3%) |
| Sep 2019 | - | -$5.06 M(-5.1%) | -$18.50 M(+9.1%) |
| Jun 2019 | - | -$5.33 M(+16.5%) | -$16.95 M(+8.5%) |
| Mar 2019 | - | -$4.58 M(+29.2%) | -$15.62 M(-2.0%) |
| Dec 2018 | -$15.94 M(-40.9%) | -$3.54 M(+0.9%) | -$15.94 M(-18.2%) |
| Sep 2018 | - | -$3.51 M(-12.1%) | -$19.49 M(-10.8%) |
| Jun 2018 | - | -$3.99 M(-18.4%) | -$21.85 M(-14.2%) |
| Mar 2018 | - | -$4.89 M(-31.0%) | -$25.46 M(-5.5%) |
| Dec 2017 | -$26.95 M(-7.2%) | -$7.10 M(+21.0%) | -$26.95 M(+6.8%) |
| Sep 2017 | - | -$5.86 M(-23.0%) | -$25.24 M(+1.0%) |
| Jun 2017 | - | -$7.61 M(+19.3%) | -$25.00 M(+0.9%) |
| Mar 2017 | - | -$6.38 M(+18.4%) | -$24.79 M(-13.8%) |
| Dec 2016 | -$29.03 M(-68.9%) | -$5.39 M(-4.2%) | -$28.74 M(-58.3%) |
| Sep 2016 | - | -$5.62 M(-24.0%) | -$68.94 M(-6.2%) |
| Jun 2016 | - | -$7.40 M(-28.4%) | -$73.47 M(-14.3%) |
| Mar 2016 | - | -$10.33 M(-77.3%) | -$85.74 M(-8.2%) |
| Dec 2015 | -$93.44 M(+77.5%) | -$45.59 M(+349.0%) | -$93.44 M(+58.9%) |
| Sep 2015 | - | -$10.15 M(-48.4%) | -$58.80 M(-9.5%) |
| Jun 2015 | - | -$19.66 M(+9.1%) | -$65.00 M(+13.2%) |
| Mar 2015 | - | -$18.03 M(+64.6%) | -$57.41 M(+9.1%) |
| Dec 2014 | -$52.63 M(+42.9%) | -$10.96 M(-33.0%) | -$52.63 M(-1.9%) |
| Sep 2014 | - | -$16.36 M(+35.5%) | -$53.62 M(+16.5%) |
| Jun 2014 | - | -$12.07 M(-8.8%) | -$46.04 M(+10.1%) |
| Mar 2014 | - | -$13.24 M(+10.8%) | -$41.80 M(+13.5%) |
| Dec 2013 | -$36.82 M(+11.1%) | -$11.95 M(+36.3%) | -$36.82 M(+0.1%) |
| Sep 2013 | - | -$8.77 M(+11.9%) | -$36.77 M(+2.8%) |
| Jun 2013 | - | -$7.83 M(-5.2%) | -$35.78 M(+4.2%) |
| Mar 2013 | - | -$8.27 M(-30.6%) | -$34.35 M(+3.6%) |
| Dec 2012 | -$33.15 M(+8.8%) | -$11.90 M(+53.0%) | -$33.15 M(+25.1%) |
| Sep 2012 | - | -$7.78 M(+21.6%) | -$26.50 M(+3.3%) |
| Jun 2012 | - | -$6.40 M(-9.5%) | -$25.65 M(-10.7%) |
| Mar 2012 | - | -$7.07 M(+34.7%) | -$28.74 M(+7.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | -$30.48 M(+130.4%) | -$5.25 M(-24.3%) | -$26.79 M(+5.0%) |
| Sep 2011 | - | -$6.93 M(-26.9%) | -$25.50 M(+10.0%) |
| Jun 2011 | - | -$9.48 M(+85.2%) | -$23.18 M(+41.8%) |
| Mar 2011 | - | -$5.12 M(+29.3%) | -$16.35 M(+23.6%) |
| Dec 2010 | -$13.23 M(-47.4%) | -$3.96 M(-14.0%) | -$13.23 M(-36.4%) |
| Sep 2010 | - | -$4.61 M(+73.4%) | -$20.81 M(-11.0%) |
| Jun 2010 | - | -$2.66 M(+32.5%) | -$23.38 M(-7.9%) |
| Mar 2010 | - | -$2.00 M(-82.6%) | -$25.39 M(+0.7%) |
| Dec 2009 | -$25.16 M(+176.1%) | -$11.54 M(+60.7%) | -$25.21 M(+57.2%) |
| Sep 2009 | - | -$7.18 M(+54.2%) | -$16.04 M(+49.1%) |
| Jun 2009 | - | -$4.66 M(+154.9%) | -$10.76 M(+27.5%) |
| Mar 2009 | - | -$1.83 M(-22.9%) | -$8.43 M(-7.5%) |
| Dec 2008 | -$9.11 M(-12.2%) | -$2.37 M(+24.6%) | -$9.11 M(+0.6%) |
| Sep 2008 | - | -$1.90 M(-18.5%) | -$9.06 M(-21.0%) |
| Jun 2008 | - | -$2.33 M(-6.9%) | -$11.47 M(+3.5%) |
| Mar 2008 | - | -$2.51 M(+8.2%) | -$11.08 M(+6.7%) |
| Dec 2007 | -$10.39 M(+133.3%) | -$2.32 M(-46.3%) | -$10.38 M(+6.2%) |
| Sep 2007 | - | -$4.31 M(+121.5%) | -$9.77 M(+53.2%) |
| Jun 2007 | - | -$1.95 M(+7.6%) | -$6.38 M(+18.3%) |
| Mar 2007 | - | -$1.81 M(+5.9%) | -$5.39 M(+21.2%) |
| Dec 2006 | -$4.45 M(+179.4%) | -$1.71 M(+86.4%) | -$4.45 M(+37.7%) |
| Sep 2006 | - | -$916.50 K(-4.6%) | -$3.23 M(+13.1%) |
| Jun 2006 | - | -$960.40 K(+10.9%) | -$2.86 M(+26.9%) |
| Mar 2006 | - | -$865.90 K(+76.7%) | -$2.25 M(+41.4%) |
| Dec 2005 | -$1.59 M(+9.1%) | -$490.00 K(-9.5%) | -$1.59 M(+17.4%) |
| Sep 2005 | - | -$541.70 K(+52.4%) | -$1.36 M(+10.5%) |
| Jun 2005 | - | -$355.40 K(+72.5%) | -$1.23 M(-4.5%) |
| Mar 2005 | - | -$206.00 K(-18.9%) | -$1.29 M(-12.0%) |
| Dec 2004 | -$1.46 M(+63.4%) | -$253.90 K(-38.6%) | -$1.46 M(-7.3%) |
| Sep 2004 | - | -$413.30 K(+0.1%) | -$1.58 M(+15.9%) |
| Jun 2004 | - | -$412.80 K(+8.4%) | -$1.36 M(+18.1%) |
| Mar 2004 | - | -$380.70 K(+3.1%) | -$1.15 M(+28.8%) |
| Dec 2003 | -$893.70 K(-21.1%) | -$369.20 K(+87.8%) | -$894.00 K(+1.4%) |
| Sep 2003 | - | -$196.60 K(-4.0%) | -$881.90 K(-3.1%) |
| Jun 2003 | - | -$204.70 K(+65.7%) | -$910.30 K(+1.3%) |
| Mar 2003 | - | -$123.50 K(-65.4%) | -$898.70 K(-20.6%) |
| Dec 2002 | -$1.13 M(-21.9%) | -$357.10 K(+58.7%) | -$1.13 M(-4.5%) |
| Sep 2002 | - | -$225.00 K(+16.5%) | -$1.19 M(-9.3%) |
| Jun 2002 | - | -$193.10 K(-46.0%) | -$1.31 M(-8.5%) |
| Mar 2002 | - | -$357.30 K(-13.1%) | -$1.43 M(+1.3%) |
| Dec 2001 | -$1.45 M(-38.6%) | -$411.00 K(+18.7%) | -$1.41 M(-13.9%) |
| Sep 2001 | - | -$346.30 K(+9.9%) | -$1.64 M(-28.2%) |
| Jun 2001 | - | -$315.10 K(-6.9%) | -$2.28 M(-5.4%) |
| Mar 2001 | - | -$338.30 K(-47.1%) | -$2.41 M(+4.6%) |
| Dec 2000 | -$2.36 M(+150.9%) | -$639.20 K(-35.5%) | -$2.31 M(+38.3%) |
| Sep 2000 | - | -$991.30 K(+122.7%) | -$1.67 M(+146.6%) |
| Jun 2000 | - | -$445.20 K(+92.6%) | -$676.40 K(+192.6%) |
| Mar 2000 | - | -$231.20 K | -$231.20 K |
| Dec 1999 | -$941.50 K(+121.7%) | - | - |
| Dec 1998 | -$424.70 K(+92.0%) | - | - |
| Mar 1998 | -$221.20 K(-11.9%) | - | - |
| Mar 1997 | -$251.20 K(-1.6%) | - | - |
| Mar 1996 | -$255.30 K | - | - |
FAQ
- What is Lisata Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Lisata Therapeutics?
- What is Lisata Therapeutics annual EBITDA year-on-year change?
- What is Lisata Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Lisata Therapeutics?
- What is Lisata Therapeutics quarterly EBITDA year-on-year change?
- What is Lisata Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Lisata Therapeutics?
- What is Lisata Therapeutics TTM EBITDA year-on-year change?
What is Lisata Therapeutics annual EBITDA?
The current annual EBITDA of LSTA is -$25.52 M
What is the all time high annual EBITDA for Lisata Therapeutics?
Lisata Therapeutics all-time high annual EBITDA is -$221.20 K
What is Lisata Therapeutics annual EBITDA year-on-year change?
Over the past year, LSTA annual EBITDA has changed by +$32.01 M (+55.64%)
What is Lisata Therapeutics quarterly EBITDA?
The current quarterly EBITDA of LSTA is -$5.29 M
What is the all time high quarterly EBITDA for Lisata Therapeutics?
Lisata Therapeutics all-time high quarterly EBITDA is -$123.50 K
What is Lisata Therapeutics quarterly EBITDA year-on-year change?
Over the past year, LSTA quarterly EBITDA has changed by +$684.00 K (+11.44%)
What is Lisata Therapeutics TTM EBITDA?
The current TTM EBITDA of LSTA is -$23.30 M
What is the all time high TTM EBITDA for Lisata Therapeutics?
Lisata Therapeutics all-time high TTM EBITDA is -$231.20 K
What is Lisata Therapeutics TTM EBITDA year-on-year change?
Over the past year, LSTA TTM EBITDA has changed by +$2.21 M (+8.68%)